Gilead's Hepcludex Secures FDA Approval: Implications for Pharma

Key Takeaways

• FDA accelerated approval covers Hepcludex 8.5 mg once-daily subcutaneous injection for adults with chronic HDV without cirrhosis or with compensated cirrhosis.
• Evidence centers on Phase 3 MYR301 (NCT03852719), which compared immediate bulevirtide dosing with delayed treatment through Week 48.
• Gilead said the product is the first and only FDA-approved HDV treatment in the United States.
• Labeling carries a boxed warning on posttreatment severe acute exacerbation of hepatitis D and B if therapy stops.

What happened with Hepcludex at FDA?

Gilead Sciences announced that FDA granted accelerated approval for Hepcludex (bulevirtide-gmod) 8.5 mg for adults living with chronic hepatitis delta virus (HDV) infection.

Company materials dated around May 22, 2026 describe Hepcludex as the first and only approved HDV treatment in the United States and position the product as an NTCP-directed HDV attachment inhibitor.

Prescribing information lists initial U.S. approval in 2026 and states the indication is for chronic HDV infection in adults without cirrhosis or with compensated cirrhosis.

What did MYR301 show?

According to Gilead, accelerated approval rests on reductions in HDV RNA and normalization of alanine aminotransferase (ALT), supported primarily by the pivotal controlled Phase 3 MYR301 study.

At Week 48, MYR301 showed a statistically significant improvement versus the delayed-treatment control group on a combined virologic and biochemical response. Gilead and the label both state that improvement in disease-related clinical outcomes has not been established.

The trial is registered as NCT03852719 on ClinicalTrials.gov: an open-label, randomized Phase 3 study of subcutaneous bulevirtide 2 mg or 10 mg once daily versus delayed treatment in chronic hepatitis delta.

Registry details show the study started in 2019, with primary completion in 2020 and overall completion in 2024, and continued treatment through Week 144 with off-treatment follow-up.

How does accelerated approval constrain claims?

Accelerated approval means the FDA accepted a surrogate endpoint package — HDV RNA decline plus ALT normalization — while requiring confirmatory benefit evidence.

Gilead said a confirmatory long-term outcomes study has already been initiated. Continued approval may be contingent on verification of clinical benefit.

Commercial teams should therefore avoid implying mortality, transplant, or cirrhosis-regression benefit until confirmatory results are public.

What safety issues matter for launch teams?

The U.S. prescribing information carries a boxed warning for posttreatment severe acute exacerbation of hepatitis D and B.

Patient labeling warns that HDV or HBV infection may flare if Hepcludex is stopped, especially in cirrhosis, and that clinicians should monitor for at least six months after discontinuation.

Hepcludex is supplied as a once-daily subcutaneous injection. Education for self-injection and refill adherence is part of launch risk management, not an optional patient-support add-on.

FDA orphan-drug records also show bulevirtide's long designation history for hepatitis D treatment (designated March 31, 2015) on FDA's orphan database.

What does this mean for hepatitis competitors and investors?

For Gilead, Hepcludex extends a viral hepatitis franchise into an indication with no prior FDA-approved therapy, which can support specialty pricing and high share of voice among hepatologists.

For competitors, the bar for late-entrant HDV assets rises: any rival will need either stronger clinical-outcome data or a more convenient regimen than daily subcutaneous dosing.

Investors should watch confirmatory-trial timelines, U.S. payer coverage criteria tied to compensated cirrhosis status, and whether European real-world experience with earlier Hepcludex authorizations transfers to U.S. uptake.

European regulatory history is separate from the U.S. accelerated approval; do not conflate EU conditional authorizations with FDA labeling without citing the specific agency decision.

Launch metrics that matter in the first two quarters include prior-authorization turnaround, specialty-pharmacy dispense rates, and how often payers require documented compensated cirrhosis status before covering the 8.5 mg daily injection.

Medical affairs teams should keep MYR301 Week 48 combined-response language aligned with the label and avoid extrapolating posttreatment undetectability rates from later congress datasets into U.S. promotional claims.

Related NovaPharma coverage

• Bulevirtide / Hepcludex drug profile
• Hepatitis D disease hub
• Related FDA approval coverage

Frequently Asked Questions

Primary Sources

• ClinicalTrials.gov NCT03852719 (MYR301)
• FDA Orphan Drug Designations: bulevirtide for hepatitis D
• Journal of Hepatology / DOI: MYR301 144-week and posttreatment results